Skip to main content
GENB $9.54 -8.00%
GENB logo
GENB · Generate Biomedicines, Inc.
Track GENB — free
$9.54 -0.83 (-8.00%) At close · Nov 20
Market Cap
$1.23B
Shares
129.10M
Volume · Nov 20 967.86K Avg daily vol (3M) 1.23M
All webcasts

Earnings call · FY2026 Q3

Generate Biomedicines, Inc. (GENB) Q3 2026 Earnings Call

Concluded Nov 12, 2026
Nov 12, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $4.22M -56.2% YoY
Diluted EPS -$0.68
Net income -$87.66M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 12, 2026
Generate Biomedicines reported a $87.7 million net loss and $404.2 million in cash, cash equivalents, and marketable securities as of Sept. 30, 2026; it believes resources including $30.0 million from Zealand will fund its current operating plan into the first half of 2028.
10-Q report · filed Nov 12, 2026
Generate Biomedicines reported a $216.6 million net loss and $204.4 million in research and development expenses for the nine months ended September 30, 2026; cash, cash equivalents and marketable securities totaled $404.2 million as of September 30, 2026.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document